Clinical Trial Update: Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer [Phase 4]

View source ↗

Summary

A Phase 4 study is evaluating chemotherapy plus bevacizumab as neoadjuvant therapy for HER2-negative breast cancer. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Solid Tumor | Phase 4 | Status: RECRUITING